38 citations
,
July 2020 in “EMBO journal” SIRT7 protein is crucial for starting hair growth in mice.
1 citations
,
February 2012
16 citations
,
March 2017 in “Oncotarget” SOCS3 treatment can prevent hair loss by stopping harmful immune responses.
7 citations
,
September 2017 in “Scientific Reports” Mice with too much sPLA₂-IIA have hair loss and poor wound healing due to abnormal hair growth and stem cell depletion.
July 2005 in “Hair transplant forum international”
September 2015 in “Dermatologic Surgery” Computer-aided imaging system accurately measures baldness in Chinese women with hair loss.
November 2024 in “Journal of Investigative Dermatology” Secukinumab reduces immune activity in hidradenitis suppurativa skin.
January 1995 in “Expert Systems with Applications” 20 citations
,
May 2023 in “Non-coding RNA Research” New delivery systems are improving siRNA treatments for skin conditions.
January 1997 in “International Society of Hair Restoration Surgery”
Ion sequential therapy improves heart function after a heart attack.
56 citations
,
September 2013 in “Experimental Dermatology” The guide explains how to study human and mouse sebaceous glands using various staining and imaging techniques, and emphasizes the need for standardized assessment methods.
June 2025 in “Revista Ciencia Multidisciplinaria CUNORI” Early intervention is crucial for managing blood clotting issues in pregnant women with COVID-19.
April 2024 in “Molecules/Molecules online/Molecules annual” The composite sponge helps heal diabetic wounds by reducing inflammation and promoting new blood vessel growth.
1 citations
,
January 2014 in “Journal of Cosmetics, Dermatological Sciences and Applications” The document's conclusion cannot be provided because the content is not available to parse.
84 citations
,
March 2010 in “Infectious Disease Clinics of North America” The document concludes that rapid identification, isolation, and strict infection control are crucial to manage SARS outbreaks.
January 2005 in “Dialnet (Universidad de la Rioja)” Post-SSRI sexual dysfunction syndrome was formally recognized in 2006, impacting clinical practice and research.